Literature DB >> 9039078

Vascular aldosterone in genetically hypertensive rats.

Y Takeda1, I Miyamori, S Inaba, K Furukawa, H Hatakeyama, T Yoneda, H Mabuchi, R Takeda.   

Abstract

We have reported that aldosterone is synthesized and cytochrome P450aldo mRNA exists in the vasculature. To clarify the pathophysiological role of vascular aldosterone in hypertension, we compared aldosterone production in the mesenteric arteries of stroke-prone spontaneously hypertensive rats (SHRSP) with that in Wistar-Kyoto rats (WKY). The expressions of mRNA of cytochrome P450aldo, mineralocorticoid receptor, and alpha 1, Na,K-ATPase in the mesenteric arteries were compared between the two groups. Aldosterone concentration in the perfusate of the vasculature was measured by radioimmunoassay after purification with high-performance liquid chromatography. Cytochrome P450aldo and mineralocorticoid receptor mRNA levels were quantified by Southern blot analysis of the products of reverse-transcribed polymerase chain reaction. Levels of alpha 1 Na,K-ATPase mRNA were measured by Northern blot analysis. Vascular aldosterone and cytochrome P450aldo mRNA levels of 2-week-old SHRSP were significantly increased compared with those of age-matched WKY. However, vascular aldosterone in 4- and 9-week-old SHRSP did not differ from that in age-matched WKY. Expression levels of mineralocorticoid receptor mRNA in the vasculature of 4- and 9-week-old SHRSP were significantly increased compared with those in age-matched WKY. Concentrations of vascular alpha 1 Na,K-ATPase mRNA of 2-, 4-, and 9-week-old SHRSP also were significantly higher than those in age-matched WKY. These results suggest that vascular aldosterone contributes to the pathophysiology of hypertension in SHRSP in the early stage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039078     DOI: 10.1161/01.hyp.29.1.45

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

Review 1.  Aldosterone and vascular damage.

Authors:  D Duprez; M De Buyzere; E R Rietzschel; D L Clement
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 2.  Aldosterone antagonists in the treatment of hypertension and target organ damage.

Authors:  S Rajagopalan; B Pitt
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 3.  Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.

Authors:  Emmanuel L Bravo
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 4.  Aldosterone Production and Signaling Dysregulation in Obesity.

Authors:  Andrea Vecchiola; Carlos F Lagos; Cristian A Carvajal; Rene Baudrand; Carlos E Fardella
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

5.  Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.

Authors:  Ryan M Downey; Masaki Mizuno; Jere H Mitchell; Wanpen Vongpatanasin; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

6.  Feedforward activation of endothelial ENaC by high sodium.

Authors:  Stefanie Korte; Alexandra S Sträter; Verena Drüppel; Hans Oberleithner; Pia Jeggle; Claudia Grossmann; Manfred Fobker; Jerzy-Roch Nofer; Eva Brand; Kristina Kusche-Vihrog
Journal:  FASEB J       Date:  2014-05-27       Impact factor: 5.191

7.  Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms.

Authors:  Lisa A Cassis; Marc J Helton; Deborah A Howatt; Victoria L King; Alan Daugherty
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 8.  Aldosterone: good guy or bad guy in cerebrovascular disease?

Authors:  Christiné S Rigsby; William E Cannady; Anne M Dorrance
Journal:  Trends Endocrinol Metab       Date:  2005-10-06       Impact factor: 12.015

9.  Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats.

Authors:  Helmy M Siragy; Chun Xue
Journal:  Exp Physiol       Date:  2008-02-22       Impact factor: 2.969

Review 10.  Aldosterone receptor antagonists for hypertension: what do they offer?

Authors:  Danny Liew; Henry Krum
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.